IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 6:18 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 6:18 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX) due to the CAG business and the company's execution of its growth strategy.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Select Medical (SEM) Q2 Earnings Meet, Revenues Rise Y/Y
by Zacks Equity Research
Select Medical's (SEM) Q2 results reflect solid segmental revenues, attributable to higher patient days and outpatient visits. Management projects adjusted EPS of $1.86-$2.03 for 2023.
Idexx (IDXX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
IDEXX (IDXX) Q2 Earnings and Revenues Beat Estimates, View Up
by Zacks Equity Research
IDEXX (IDXX) delivers better-than-expected earnings and revenues in the second quarter of 2023, backed by CAG Diagnostics' recurring revenue growth.
Idexx Laboratories (IDXX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 9.88% and 1.70%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
IDEXX Laboratories (IDXX) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) second-quarter 2023 results are expected to reflect an impressive performance in the CAG segment.
Idexx Laboratories (IDXX) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
IDEXX (IDXX) Stock Up 18.4% YTD: Will the Rally Continue?
by Zacks Equity Research
The continued solid demand for veterinary services and benefits from strong execution poise IDEXX (IDXX) well for future growth.
IDEXX (IDXX) Launches First Veterinary Diagnostic Test
by Zacks Equity Research
IDEXX's (IDXX) Cystatin B Test can help veterinary professionals to spot kidney damage before it affects kidney function, which may result in better patient outcomes.
Here's Why You Should Invest in IDEXX (IDXX) Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX) on the strength of the Companion Animal Group business.
Idexx (IDXX) Down 2.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Encompass Health's (EHC) Q1 Earnings Beat, '23 EPS View Up
by Zacks Equity Research
Encompass Health's (EHC) Q1 results reflect improved patient volumes and higher discharge growth. Management estimates 2023 adjusted EPS within $2.94-$3.23, up from the earlier view of $2.87-$3.16.
IDEXX (IDXX) Q1 Earnings Beat Estimates, Margins Increase
by Zacks Equity Research
Continued solid demand for veterinary services and record global premium instrument placements drive IDEXX's (IDXX) Q1 revenues.
Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Idexx Laboratories (IDXX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 7.14% and 1.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of 3.51% and 9.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Alphatec (ATEC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Alphatec (ATEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Philips' (PHG) Q1 Earnings Jump Y/Y on Strong Top-Line Growth
by Zacks Equity Research
Philips' (PHG) first-quarter results benefit from robust performances by the Diagnosis & Treatment and the Connected Care businesses.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
Neogen (NEOG) New Buyouts Aid Growth Amid Rise in Expenses
by Zacks Equity Research
Neogen's (NEOG) performance of the Food Safety business is strong, driven by several long-term secular tailwinds.
AmerisourceBergen's (ABC) New JV to Boost Oncology Care
by Zacks Equity Research
AmerisourceBergen's (ABC) new JV is expected to provide the independent community oncology network with additional resources and expertise to grow the platform and improve patient outcomes.